Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 2Carcinoma, Hepatocellular 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Sorafenib 5Nivolumab 3lenvatinib 2cabozantinib 2Ipilimumab 2ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1atezolizumab 1adavosertib 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Hepatocellular × lenvatinib × Clear all
NCT04039607 2026-04-06

CheckMate 9DW

Bristol-Myers Squibb

Phase 3 Active not recruiting
732 enrolled 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Phase 3 Completed
954 enrolled 19 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡